Compare Novo Nordisk A/S (NVO) vs WEC Energy Group Inc. Common Stock (WEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs WEC Energy Group Inc. Common Stock — how do they compare? Novo Nordisk A/S trades at $38.68 (market cap $169.08B), while WEC Energy Group Inc. Common Stock trades at $107.27 (market cap $34.50B). The key difference: Novo Nordisk A/S is far larger — about 4.9× WEC Energy Group Inc. Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and WEC Energy Group Inc. Common Stock for 0 Days on average.
| NVO | WEC | |
|---|---|---|
Market Cap | $169.08B | $34.50B |
Volume | 9,259,152 | 2,835,735 |
Sector | Health | Utilities |
52-Week High | $63.98 | $118.85 |
52-Week Low | $35.29 | $100.78 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $183.28B | $57.46B |
Dividend Yield | 4.72% | 3.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
WEC Energy Group trades at $105.87, up 0.92% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $0.91 vs. $0.804 expected) and improving profitability (net margin 16.7%). Recent news highlights growing data center demand as a key growth driver, with the company engaging in large-scale customer discussions for 400-500 megawatt projects.
WEC presents a compelling utility investment with stable cash flows and dividend potential, though faces interest rate sensitivity. Analyst consensus targets $118.33 (12% upside) with majority Hold ratings. Key risks include regulatory pressures and capital expenditure requirements for infrastructure expansion through 2030.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About WEC Energy Group Inc. Common Stock
WEC Energy Group is a Midwest electric and natural gas utility holding company whose subsidiaries, including We Energies and Wisconsin Public Service, deliver electricity and natural gas to customers in Wisconsin, Illinois, Michigan, and Minnesota.
Read more on WEC →
